GSTP1 Ile105Val polymorphism in astrocytomas and glioblastomas
A C Custódio1, L O Almeida, G R Pinto
1Departamento de Genética, Laboratório de Oncogenética, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil. alinecadurin@yahoo.com.br
Genetics and Molecular Research : GMR
|December 4, 2010
Summary
Glutathione S-transferase P1 (GSTP1) Ile105Val gene variations increase the risk of developing astrocytoma and glioblastoma. This GSTP1 polymorphism is linked to higher tumor development risk but does not affect patient survival.
Area of Science:
- Biochemistry
- Genetics
- Oncology
Background:
- Glutathione S-transferases (GSTs) are crucial for detoxifying harmful compounds.
- Deficiencies in GST genes elevate cancer risk.
- GSTP1 is a key enzyme in detoxification pathways.
Purpose of the Study:
- To investigate the association between GSTP1 Ile105Val polymorphism and the risk of astrocytoma and glioblastoma.
- To determine if this polymorphism impacts patient survival.
Main Methods:
- Genotyping of GSTP1 Ile105Val polymorphism using PCR-RFLP.
- Analysis of 80 astrocytoma and glioblastoma patient samples.
Main Results:
- The Val allele of the GSTP1 Ile105Val polymorphism was significantly associated with an increased risk of tumor development (OR = 8.60, P < 0.001).
- No significant difference in overall survival was observed between patients with different GSTP1 genotypes.
Conclusions:
- GSTP1 Ile105Val polymorphisms may play a role in susceptibility to astrocytoma and glioblastoma.
- This genetic variation is a potential biomarker for tumor risk assessment.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...